Bristol Myers raises 2026 outlook as growth portfolio sales rise 12%
Bristol Myers Squibb raised its 2026 earnings guidance as growth portfolio sales rose 12% to $7.7 billion, with eight medicines now exceeding $1 billion in annualized sales. The company reported four positive late-stage trial results in two months and generated $4.2 billion in quarterly operating cash flow. Generic competition drove a 3% decline in Legacy Portfolio revenue.
Bristol Myers presents more than 90 hematology updates at ASH
Bristol Myers Squibb planned more than 90 disclosures, including 24 oral presentations, at ASH 2026. Highlights included Phase 3 iberdomide and mezigdomide results in multiple myeloma, early data on next-generation CAR T therapies, five-year Breyanzi follow-up in second-line large B-cell lymphoma, and studies of golcadomide and Reblozyl in hematologic disorders.
Bristol Myers advances neuroscience and oncology programs
Bristol Myers Squibb reported initial Phase 3 ADEPT data for KarXT in psychosis associated with Alzheimer’s disease and announced a clinical trial collaboration with Erasca to study a molecular glue approach for MTAP-deleted pancreatic cancer. The article said the programs could expand BMS’s neuroscience and oncology portfolios as it faces patent-cliff and earnings pressures, while both carry clinical execution risk.
Bristol Myers and Evotec secure FDA acceptance for second partnership IND
Evotec and Bristol Myers Squibb received FDA acceptance for a second investigational drug application under their molecular glue partnership. The CELMoD candidate is expected to enter Phase 1 trials in 2027; the partnership’s first candidate began Phase 1 testing in March 2026. The collaboration combines Evotec’s discovery platforms with BMS’s CELMoD library to develop protein-degrading therapies.
Bristol Myers faces Eliquis and clinical trial catalysts
Bristol Myers Squibb faces several catalysts over the next six months: Eliquis loses European exclusivity in fiscal Q4 2026, Phase 3 results for Milvexian and Sotyktu are expected by year-end, and additional trial results and an FDA decision follow in early 2027. Management expects Eliquis revenue to fall $1.5 billion to $2 billion in 2027, partly offset by growth portfolio sales.
Bristol Myers reports preliminary Phase 3 KarXT data in Alzheimer’s psychosis
Bristol Myers Squibb reported preliminary open-label Phase 3 ADEPT findings for KarXT in Alzheimer’s-related psychosis. In ADEPT-1, 12 weeks of treatment was associated with improvements in hallucination and delusion scores and disease severity; 85.3% of 320 enrolled participants completed the period. The findings are descriptive, and double-blind trial results remain blinded as the ADEPT program continues.
Bristol Myers and Erasca plan pancreatic cancer combination trial
Bristol Myers Squibb will sponsor a clinical trial evaluating Erasca’s investigational pan-RAS drug ERAS-0015 with BMS’s PRMT5 inhibitor navlimetostat in patients with MTAP-deleted pancreatic cancer. Erasca will supply ERAS-0015, and both companies retain rights to their compounds under a non-exclusive agreement. The combination’s safety and efficacy remain unproven.
Bristol Myers CEO warns against weakening U.S. science and biotech
Bristol Myers Squibb CEO Chris Boerner said the U.S. risks losing advantages in medicine and vaccine development if it undermines its science and biotech ecosystem. He criticized inefficiencies in drug pricing and restrictions on assistance programs and outcome-based payments. Boerner also said BMS is using AI to accelerate drug development and aims to cut clinical-to-approval time by 30%.
Bristol Myers trails the S&P 500 over five years despite dividends
Bristol Myers Squibb shares rose 3.2% over five years through Nov. 17, 2026, versus 56.7% for the S&P 500. Reinvested dividends lifted BMY’s return to 26.9%, but it still trailed the index’s 67.6% total return by 40.6 percentage points. Over the past year, BMY returned 37.4% with dividends, outperforming the index’s 10.2%.
Bristol Myers combines research and development under Cristian Massacesi
Bristol Myers Squibb will combine its research and development departments into one end-to-end organisation on 1 January 2027, led by executive vice president and chief medical officer Cristian Massacesi. Chief research officer Robert Plenge will advise through March 2027 before leaving. The company says the change will connect scientific and clinical expertise, speed decisions and strengthen portfolio execution.
Bristol Myers valuation models diverge after share gains
Bristol Myers Squibb shares have gained about 40.5% over three years and recently traded at $62.91. A Simply Wall St discounted cash flow model estimates intrinsic value substantially above that price, despite projected gradual cash-flow declines as major products mature. Investor narratives diverge, with one seeing upside based on newer therapies and another considering the stock overvalued.
Bristol Myers reports sustained 56-week Camzyos efficacy in pediatric trial
Bristol Myers Squibb reported 56-week Phase 3 SCOUT-HCM results showing sustained reductions in left ventricular outflow tract gradients and improvements in secondary measures among adolescents treated with Camzyos. No patients had LVEF below 50%, and no new safety signals emerged. The data extend evidence for the drug, which received U.S. approval for eligible pediatric patients in September 2026.
Bristol Myers dividend faces scrutiny ahead of Eliquis declines
Bristol Myers Squibb’s $2.52 annual dividend appears well covered, consuming about 38%–40% of projected 2026 earnings and 39% of 2025 free cash flow. Debt has declined, though the company faces a projected $1.5 billion–$2 billion Eliquis revenue step-down in 2027 and continued declines in older drugs. Growth Portfolio sales rose 12% to $7.66 billion.
Bristol Myers Squibb forms neuroscience AI alliance with Pathos and Tempus
The partners aim to combine patient data and AI-powered analysis to support precision medicine and clinical-trial design, including in Alzheimer’s disease. The financial impact and spending are not yet clear, and the eventual effect will depend on whether AI-generated insights produce safe, approvable therapies in time to offset patent pressures.
Bristol Myers receives accelerated FDA approval for ZENBEXUS
Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS in multiple myeloma and reported positive updates in lung cancer and multiple sclerosis. Shares have risen 20.07% year to date. The article discussed a valuation debate, patent expirations, pipeline results, earnings quality and debt as risks.
Bristol Myers highlights CELMoDs and radiopharmaceuticals as growth platforms
Bristol Myers Squibb is emphasizing CELMoDs and radiopharmaceuticals as growth platforms, while continuing to highlight immuno-oncology. CELMoDs are intended to replace declining Revlimid and Pomalyst sales in multiple myeloma; iberdomide has received accelerated FDA approval, while mezigdomide awaits a May 2027 decision. The combined Opdivo and Qvantig total of about $2.7 billion is a key metric to watch in the next quarter.
Polaris Rx was selected to dispense Bristol Myers Squibb’s ZENBEXUS (iberdomide), an FDA-approved oral treatment for adults with multiple myeloma after at least one prior line of therapy. Accelerated approval was granted August 13, 2026, based on a Phase 3 trial. Polaris Rx said its pharmacists and support teams will help patients manage treatment at home.
Bristol Myers faces a projected Eliquis sales decline in 2027
Bristol Myers Squibb expects Eliquis sales to decline by $1.5 billion to $2 billion in 2027 as it loses exclusivity in Europe, following strong 2026 growth. The anticipated drop equals about 3% to 4% of recent annual revenue, while the company’s growth medicines portfolio rose 12% in the third quarter. The company lowered its 2026 adjusted earnings outlook due to acquired research charges.
Bristol Myers licenses Tempus oncology data through 2031
The BMS agreement licenses Tempus’s multimodal oncology data through 2031 and provides access to its Lens platform. The partnerships add revenue visibility as Tempus expands its diagnostics and data businesses, though reimbursement, pharma demand, competition, and ongoing losses remain risks.
Bristol Myers raises revenue outlook and lowers adjusted EPS guidance
Bristol Myers Squibb reported Q3 2026 revenue of $13.07 billion, up 6.9% year over year and above estimates, with adjusted EPS of $1.35 also beating expectations. The company raised its full-year revenue midpoint to $50 billion but lowered adjusted EPS guidance to $6.45. Operating margin declined to 21.8% from 24.6%, reflecting higher R&D and launch costs.